• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors

    3/16/21 9:03:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNSP alert in real time by email

    LAS VEGAS, March 16, 2021 /PRNewswire/ -- Esports Technologies, Inc., a global provider of advanced esports wagering products, today announced the appointment of Christopher Downs to its Board of Directors, effective March 5, 2021. Downs will lend his years of corporate finance experience to Esports Technologies as it accelerates its growth in esports wagering. As a board member of Esports Technologies, Downs will chair the Audit Committee and serve on both the Compensation and Nominating and Governance Committees.

    Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors

    Aaron Speach, Esports Technologies Chief Executive Officer, said, "As we pursue expanding our reach in the gaming and software markets, Chris' expertise across all aspects of corporate finance and M&A will be a welcome addition to the Board."

    Downs has more than 20 years of finance experience in the banking, medical and life sciences industries. Currently, he is Chief Financial Officer for CNS Pharmaceuticals (Nasdaq: CNSP). Previously, he served in a financial leadership role at InfuSystem Holdings, Inc., as Executive Vice President and Interim Chief Financial Officer. Downs' earlier career as an investment banker included serving as a corporate finance analyst at Citigroup and several M&A boutique firms. Downs earned a Bachelor of Science in economics from the United States Military Academy at West Point, an MBA from Columbia Business School, and a Master of Science in accounting from University of Houston. He is a certified public accountant and has obtained professional designations including certified treasury professional and certified corporate financial planning and analysis professional.

    "The future of esports products and wagering is projected to grow this year and in the years ahead, and Esports Technologies is uniquely positioned in this marketplace," said Downs. "I look forward to supporting Esports Technologies' goals for growth and market penetration in the coming months and years."

    About Esports Technologies
    Esports Technologies is developing groundbreaking and engaging wagering products for esports fans and bettors around the world. Esports Technologies is a global provider of esports product, platform and marketing solutions. The company operates a licensed online gambling platform, gogawi.com, that offers real money betting on esports events and professional sports from around the world in a secure environment. The company is developing esports predictive gaming technologies that allow distribution to both customers and business partners.

    CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS: 
    This document contains forward-looking statements.  In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.  We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.  Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities.  You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.  In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business.  These and other factors may cause our actual results to differ materially from any forward-looking statement.  Forward-looking statements are only predictions.  The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us.  We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

    SOURCE Esports Technologies, Inc.

    Get the next $CNSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNSP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

      Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cureRegister for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET.For the event, John Climaco, C

      12/5/24 9:10:00 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

      Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier

      11/25/24 9:00:00 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

      HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX.Details of the presentation are as follows:Title:Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)Presenter: Sandra Silberman, MD, Ph

      11/18/24 8:56:05 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gumulka Jerzy bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 345% to 43,006 units (SEC Form 4)

      4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

      2/6/24 10:28:10 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evans Carl Anthony bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 26,666% to 33,458 units (SEC Form 4)

      4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

      2/6/24 10:27:56 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Downs Christopher bought $20,000 worth of shares (66,666 units at $0.30), increasing direct ownership by 181% to 103,438 units (SEC Form 4)

      4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

      2/6/24 10:27:39 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital initiated coverage on CNS Pharmaceuticals with a new price target

      Brookline Capital initiated coverage of CNS Pharmaceuticals with a rating of Buy and set a new price target of $10.00

      2/2/21 10:31:34 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CNS Pharmaceuticals Inc.

      SC 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

      11/14/24 3:58:53 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by CNS Pharmaceuticals Inc.

      SC 13D - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

      8/2/24 4:11:48 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CNS Pharmaceuticals Inc.

      SC 13G - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

      7/2/24 12:34:25 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Cortice Biosciences, Inc.

      4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

      8/6/24 5:11:50 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Cortice Biosciences, Inc. claimed ownership of 573,368 shares (SEC Form 3)

      3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

      8/6/24 4:53:41 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mahery Amy

      4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

      4/10/24 9:53:15 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNSP
    Leadership Updates

    Live Leadership Updates

    See more
    • Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

      Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunologyHOUSTON, TX / ACCESSWIRE / January 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Amy Mahery to its Board of Directors, effective upon completion of a financing. Ms. Mahery, who currently serves as the Chief Commercial Officer of Roivant Sciences, a $9 Billion market cap b

      1/18/24 8:45:00 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

      Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON, Jan. 3, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Faith L. Charles as Chair of its Board of Directors. "The depth and breadth of knowledge, experience and network that Fait

      1/3/23 12:00:00 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors

      LAS VEGAS, March 16, 2021 /PRNewswire/ -- Esports Technologies, Inc., a global provider of advanced esports wagering products, today announced the appointment of Christopher Downs to its Board of Directors, effective March 5, 2021. Downs will lend his years of corporate finance experience to Esports Technologies as it accelerates its growth in esports wagering. As a board member of Esports Technologies, Downs will chair the Audit Committee and serve on both the Compensation and Nominating and Governance Committees. Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors Aaron Speach, Esp

      3/16/21 9:03:00 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNSP
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by CNS Pharmaceuticals Inc.

      10-K/A - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

      4/30/25 4:30:10 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by CNS Pharmaceuticals Inc.

      S-1 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

      4/14/25 5:01:16 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

      4/9/25 3:32:24 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care